Jacobs (NYSE:J) and PA Consulting, a leading innovation and transformation consultancy, have reached an agreement for Jacobs to acquire the remaining stake in PA Consulting, which is primarily held by PA existing and former employees. Jacobs' further investment in PA creates a global advisory powerhouse for clients – delivering solutions that enhance capital efficiency, accelerate innovation and drive lasting value.
The total upfront consideration for the remaining stake will be approximately £1.216 billion ($1.6 billion), reflecting a valuation for 100% of the business of approximately £3.05 billion, or 13.0x expected calendar year 2025 adjusted EBITDA2 before synergies, and 12.3x including estimated synergies. The transaction also includes £75 million in deferred consideration which is expected to be paid in Jacobs' shares valued on the second anniversary of the transaction closing. The transaction has been unanimously approved by Jacobs' Board of Directors and PA's Stakeholder Representatives. PA's Stakeholder Representatives and members of the key leadership team have given irrevocable undertakings to vote in favor of the transaction.
Jacobs Chair and CEO Bob Pragada said: "Since our strategic investment in March 2021, our collaboration with PA Consulting has accelerated profitable growth and reinforced Jacobs' leadership as we redefine the asset lifecycle — embedding us earlier in client journeys and expanding our impact across strategy, transformation and advisory. Jacobs' deep understanding of infrastructure delivery, capital asset cycles and highly technical program management complement PA Consulting's strategic advisory, innovation and transformation capabilities – together enabling us to transform bold ideas into practical, optimized outcomes for our clients."
"This is a key milestone for our business and underscores our disciplined approach for return-focused capital allocation and our priority to drive sustained value creation," Pragada added. "Our partnership during the past 4+ years demonstrates we are positioned to enhance Jacobs' margin profile even further and unlock synergies, including new cross-sell opportunities."
PA Consulting CEO Christian Norris said: "By fully bringing together the expertise of PA and Jacobs, we can better empower clients to overcome today's complexities and embrace tomorrow's opportunities with confidence. We know that, together, we're making a positive difference to businesses, economies and societies. Investing and extending PA's valuable brand and positioning in innovation and transformation consulting will enable us to tackle the broadest range of client challenges. Looking ahead, I'm excited to build on what we've achieved for clients so far and deliver even greater impact as one global company."
Strategic and Financial Rationale for the Combination
The transaction represents the next step in the collaboration between Jacobs and PA Consulting and is expected to bring multiple strategic and financial benefits:
Transaction Terms and Financing
The transaction is structured with Jacobs acquiring the remaining stake of PA Consulting, which is primarily held by PA existing and former employees, for upfront consideration of approximately £1.216 billion, which is inclusive of expected adjustments up through the anticipated closing date. The upfront consideration, net of certain transaction expenses payable by the shareholders, will be paid 80% in cash and 20% in Jacobs' shares.
The transaction also includes deferred consideration of £75 million which is payable in Jacobs' shares as valued on the two-year anniversary following closing, cash, or a combination thereof, at Jacobs' election. Jacobs intends to fund the cash portion of the upfront consideration through a combination of cash-on-hand and existing and incremental debt facilities.
The transaction will primarily be implemented by way of a U.K. Scheme of Arrangement and is subject to the satisfaction of customary closing conditions, including the approval of the current shareholders of PA and the U.K. Court (pursuant to the Scheme). The transaction is expected to close by the end of Jacobs' fiscal 2026 second quarter.